BOSTON–PerkinElmer, Inc. (NYSE: PKI – News), a global leader in Health Sciences and Photonics markets, announced the appointment of Dr. Daniel R. Marshak as vice president and chief scientific officer for the Company. Marshak will be responsible for setting the strategic direction of PerkinElmer’s research and development functions, and helping drive its growth strategies in the emerging areas of personalized medicine and predictive diagnostics. Marshak brings more than 25 years of life sciences experience to his position and joins PerkinElmer from Cambrex Corporation (NYSE: CBM – News) where he served as vice president and chief technology officer. In this role, he led major research and business development initiatives for Cambrex’s bioscience units worldwide. Marshak currently serves as an adjunct associate professor at Johns Hopkins University School of Medicine. He is an inventor of six series of patents and author of more than 100 articles and abstracts. Marshak holds a Ph.D. from The Rockefeller University in New York, New York, and a Bachelor of Arts degree in Biochemistry & Molecular Biology from Harvard University, Cambridge, Massachusetts. He holds numerous patents in stem cell research, has served on the American Association for the Advancement of Science working group on the Ethics of Stem Cell Research, and currently serves as an advisor to PharmaFrontiers Corp. (OTCBB: PFTR – News), a cellular therapy company developing treatments for diseases including multiple sclerosis and diabetes, and Ortec International, Inc. (US: ORTN), a leading tissue-engineering and advanced wound care company.